Skip to content
Clinical Trials – home
Not yet recruiting

Safety and efficacy of PALIRODEN ear injection in participants with type 2 diabetes and cochlear synaptopathy

Verified siteFast replyInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on people who have type 2 diabetes and a hearing problem called Cochlear Synaptopathy, which makes it hard to understand speech when there is background noise. Participants receive a single injection of a new drug named Paliroden placed directly into the middle ear through a small opening in the eardrum (this is called a transtympanic injection). Some participants receive a harmless gel that looks the same but does not contain the active drug, serving as a control.

The purpose of the study is to determine whether the injection is safe and whether it can improve the ability to hear speech in noisy situations. After the injection, participants are monitored for several months with regular check‑ins to record any side effects and to test hearing performance, especially how well they can understand spoken words amid background sounds. Simple explanations are provided for any technical terms used during the visits.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Consent

    You will be asked to read and sign a consent form that explains the purpose of the study, the procedures involved, and any possible risks.

    After signing, you will be officially enrolled as a participant in the trial.

  2. Step 2

    Baseline Assessments

    A series of tests will be performed to record your current health status, including a medical history review, blood sample collection, and hearing evaluations that measure how well you understand speech in noisy environments.

    These results will serve as the reference point for all future comparisons during the study.

  3. Step 3

    Transtympanic Injection of <b>Paliroden</b>

    You will receive a single injection of Paliroden (or a matching placebo) directly into the middle ear through the eardrum, a procedure known as a transtympanic injection.

    The medication is supplied as a suspension for injection; the exact amount administered is determined by the study protocol and is given only once.

  4. Step 4

    Immediate Post‑Injection Monitoring and Blood Sampling

    Shortly after the injection, you will stay at the clinic for a series of blood draws to measure how the drug is processed in your body.

    Blood samples will be taken at the following times: before the injection (baseline), 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 8 hours, 24 hours, 72 hours (Day 3), 168 hours (Day 7), and 672 hours (Day 28) after the injection.

  5. Step 5

    Early Follow‑Up Visits (Day 3 and Day 7)

    You will return to the clinic on Day 3 and Day 7 for safety checks, which include a brief physical examination and review of any symptoms you may have experienced.

    Additional blood samples may be collected on these days as part of the safety monitoring.

  6. Step 6

    Mid‑Study Follow‑Up Visits (Day 28, Day 84)

    At Day 28 and Day 84, you will attend clinic visits that combine safety assessments with hearing tests.

    The hearing tests will evaluate improvement in your ability to understand speech in noise, and other measurements such as electrocochleography and auditory brain‑stem response may be performed.

    Blood samples may also be taken to continue monitoring the drug’s behavior in the body.

  7. Step 7

    Final Follow‑Up Visit (Day 168)

    Six months after the injection (Day 168), you will complete the final study visit.

    This visit includes a comprehensive safety review, repeat hearing assessments, and collection of any remaining questionnaire responses about your hearing experience.

    The results from this visit will be used to determine the overall safety and possible benefit of Paliroden.

Who can join the trial?

12 criteria

  • Signed and dated informed consent form confirming you agree to take part in the study.
  • Age between 45 and 75 years at the time of screening.
  • Diagnosed with type 2 diabetes for at least 5 years and a recent blood test showing hemoglobin A1c between 7% and 9% (a measure of average blood sugar control).
  • Considered by the study doctor to be reliable and able to follow the study schedule.
  • Must be a native speaker of the language used for study assessments in the country where the study is taking place.
  • Normal hearing in the lower frequencies, measured as average hearing threshold (PTAv) below 25 decibels (dB) for frequencies 0.5, 1, 2 and 4 kHz in both ears.
  • Allowed up to mild hearing loss in the higher frequencies, measured as average high‑frequency hearing (PTAvHF) below 40 dB for frequencies 4, 6 and 8 kHz in both ears.
  • Presence of otoacoustic emissions of at least 7 dB signal‑to‑noise ratio at three different test frequencies (1, 2, 4 or 8 kHz), showing the inner ear can still produce sound.
  • Demonstrated a speech‑in‑noise deficit, meaning you need at least 3 dB more signal than background noise than a normal reference score on the Matrix test, in both ears.
  • If you are a woman who could become pregnant, you must have a negative urine and serum pregnancy test before starting the study and agree to use a highly effective birth‑control method (such as hormonal pills, IUD, or sterilization) during the study and for 30 days after the last dose.
  • If you are a man with a partner who could become pregnant, you must use a barrier method (like a condom) and ensure your partner uses a highly effective birth‑control method during the same period.
  • You must be willing and able to keep water out of your ear canal and middle ear until the eardrum is fully healed after the injection.

Who cannot join the trial?

22 criteria

  • If your score on the MoCA (a short test of memory and thinking) is lower than 26, you cannot join the study.
  • If you had major surgery in the 8 weeks before screening, or plan to have major surgery during the study period, you are excluded.
  • If you have any known ear disease such as autoimmune hearing loss, hearing loss caused by radiation, hearing that comes and goes, inner‑ear fluid problems (called endolymphatic hydrops), or Menière’s disease, you cannot participate.
  • If you currently have middle‑ear problems or infections (for example, active otitis media, other ear infections, or a hole in the eardrum), you are not eligible.
  • If you have a history of cancer that was treated with platinum‑based chemotherapy, you are excluded.
  • If you have any other cancer that still needs treatment and is not stable, you cannot join.
  • If you have evidence or a history of problems behind the inner ear (called retrocochlear pathology, for example an acoustic neuroma tumor), you are not eligible.
  • If you are currently pregnant, breastfeeding, have a positive pregnancy test, or plan to become pregnant during the study, you cannot participate.
  • If you have had ear surgery in the past (except for a simple ear‑tube placement more than one year ago), you are excluded.
  • If an ear exam shows that less than 90 % of your eardrum can be seen because of earwax blockage or a perforated eardrum, you cannot join unless the blockage is removed before the baseline visit.
  • If you use hearing aids or have a cochlear implant, you are not eligible.
  • If recent blood tests show liver problems—specifically, bilirubin more than twice the normal limit, or liver enzymes (ALT or AST) or GGT more than five times the normal limit—you cannot participate.
  • If you have diabetes that was inherited from your mother (maternal inherited diabetes), you are excluded.
  • If you were born with hearing loss (congenital hearing loss), you cannot join.
  • If you have hypothyroidism that has not been treated, you are not eligible.
  • If you are an adult who cannot give legal consent because of guardianship, incarceration, or similar legal protection, you cannot participate.
  • If you are currently taking part in another clinical trial or have taken an experimental drug within the past 30 days (or five half‑lives of that drug, whichever is longer), you are excluded.
  • If you have diagnosed mental health conditions such as anxiety disorders, psychosis, major depression, schizophrenia, a history of suicide attempts, or other serious psychiatric issues that could affect your ability to follow the study plan, you cannot join.
  • If an ear exam (otoscopy) at baseline shows less than 90 % of the eardrum visible (due to earwax or perforation) and it cannot be cleared before treatment, you are excluded.
  • If a hearing test called a tympanogram shows any result other than a normal “type A” pattern, you cannot participate.
  • If you have a conductive hearing loss—meaning the difference between air‑ and bone‑conduction hearing thresholds is more than 10 dB and air‑conduction thresholds are above 20 dB— you are excluded.
  • If the hearing levels in your two ears differ by more than 15 dB (asymmetric hearing thresholds), you cannot join the study.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Paliroden is a medication being tested in this study as a single injection into the middle ear (transtympanic injection). It is a liquid suspension that is placed directly near the inner ear. The purpose of the injection is to see if the drug can help protect or repair the connections between the hearing nerve cells (cochlear synapses) that may be damaged in people with type 2 diabetes. Researchers are looking at how safe the medicine is and whether it can improve the ability to understand speech when there is background noise, which is a common problem for people with this type of hearing issue.

What is already known about the treatment

Paliroden - Paliroden is given as a single transtympanic injection, meaning a small amount of a liquid suspension is placed directly into the middle ear through the eardrum. It is an experimental drug currently being studied in early‑phase clinical trials and is not yet approved for general medical use. The medicine is being tested to help people with type 2 diabetes who have cochlear synaptopathy, a condition that makes hearing in noisy environments difficult. Paliroden works by protecting and repairing the tiny connections between hearing cells and nerves, acting as a neuroprotective agent, and it belongs to the class of neuroprotective otologic agents.

Investigated diseases

  • Cochlear synaptopathy

    A condition in which the connections between the inner ear hair cells and the auditory nerve are damaged, reducing the ability to hear soft sounds and understand speech in noisy environments. The damage often begins subtly and can progress slowly, especially when exposed to loud noise or metabolic stress, leading to increasing difficulty distinguishing sounds over time.

  • Type 2 diabetes mellitus

    A chronic metabolic disorder in which the body becomes resistant to insulin or does not produce enough, resulting in elevated blood glucose levels. Over months and years, high glucose can gradually affect blood vessels and nerves throughout the body, causing symptoms that may worsen if blood sugar remains uncontrolled.

Trial detailsLast updated 19 Nov 2026
Age18+ yearsPhasePhase ITrial ID2025-524383-37-00Protocol codeRESPLANDEstimated enrolment60 patientsSponsorCilcare

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.